In fact, a major line of research in the field currently focuses on the use of broadly neutralizing antibodies (bNAbs) as a therapeutic or prophylactic treatment for HIV infection, relying on the efficient blocking of the virus and the triggering of potent immune effector responses, for example, through FcγR interactions (Hessell et al., 2007; Bournazos et al., 2014). This evidence concerns the gene FCGR2A and HIV infectious disease.